Asenapine

Medical uses

Asenapine has been approved by the FDA for the acute treatment of adults with schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. In Australia asenapine's approved (and also listed on the PBS) indications include the following:

• Schizophrenia
• Treatment, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder
• Maintenance treatment, as monotherapy, of bipolar I disorder

In the European Union and the United Kingdom, asenapine is only licensed for use as a treatment for acute mania in bipolar I disorder.

Asenapine is absorbed readily if administered sublingually, but is poorly absorbed when swallowed. A transdermal formulation of asenapine was approved in the United States in October 2019 under the brand name Secuado.

Schizophrenia

A Cochrane systematic review found that while Asenapine has some preliminary evidence that it improves positive, negative, and depressive symptoms, it does not have enough research to merit a certain recommendation of asenapine for the treatment of schizophrenia.

Bipolar disorder

For the medium-term and long-term management and control of both depressive and manic features of bipolar disorder asenapine was found to be equally effective as olanzapine, but with a substantially superior side effect profile.

In acute mania, asenapine was found to be significantly superior to placebo. As for its efficacy in the treatment of acute mania, a recent meta-analysis showed that it produces comparatively small improvements in manic symptoms in patients with acute mania and mixed episodes than most other antipsychotic drugs such as risperidone and olanzapine (with the exception of ziprasidone). Drop-out rates (in clinical trials) were also unusually high with asenapine. According to a post-hoc analysis of two 3-week clinical trials it may possess some antidepressant effects in patients with acute mania or mixed episodes.

Adverse effects

Adverse effect incidence

Very common (10% incidence) adverse effects include:

• Somnolence Common (1–10% incidence) adverse effects include:
• Weight gain
• Increased appetite
• Extrapyramidal side effects (EPS; such as dystonia, akathisia, dyskinesia, muscle rigidity, parkinsonism)
• Sedation
• Dizziness
• Dysgeusia (altered taste)
• Oral hypoaesthesia (numbness), only when taken sublingually. Transdermal asenapine was shown to eliminate this side effect.
• Increased alanine aminotransferase
• Dyspepsia, stomach discomfort, and/or vomiting
• Fatigue

Uncommon (0.1–1% incidence) adverse effects include:

• Hyperglycaemia — elevated blood glucose (sugar)
• Syncope
• Seizure
• Dysarthria
• sinus bradycardia
• Bundle branch block
• QTc interval prolongation (has a relatively low risk for causing QTc interval prolongation.)
• sinus tachycardia
• Orthostatic hypotension
• Hypotension
• Swollen tongue
• Dysphagia (difficulty swallowing)
• Glossodynia
• Oral paraesthesia

Rare (0.01–0.1% incidence) adverse effects include:

• Neuroleptic malignant syndrome (Combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness, and sudden change in blood pressure and heart rate)
• Tardive dyskinesia
• Speech disturbance
• Rhabdomyolysis
• Angioedema
• Blood dyscrasias such as agranulocytosis, leukopenia and neutropenia
• Accommodation disorder
• Pulmonary embolism
• Gynaecomastia
• Galactorrhoea

Unknown incidence adverse effects

• Allergic reaction
• Restless legs syndrome
• Oral mucosal lesions (ulcerations, blistering and inflammation)
• Salivary hypersecretion
• Hyperprolactinaemia

Asenapine seems to have a relatively low weight gain liability for an atypical antipsychotic (which are notorious for their metabolic side effects) and a 2013 meta-analysis found significantly less weight gain (SMD [standard mean difference in weight gained in those on placebo vs. active drug]: 0.23; 95% CI: 0.07-0.39) than, paliperidone (SMD: 0.38; 95% CI: 0.27-0.48), risperidone (SMD: 0.42; 95% CI: 0.33-0.50), quetiapine (SMD: 0.43; 95% CI: 0.34-0.53), sertindole (SMD: 0.53; 95% CI: 0.38-0.68), chlorpromazine (SMD: 0.55; 95% CI: 0.34-0.76), iloperidone (SMD: 0.62; 95% CI: 0.49-0.74), clozapine (SMD: 0.65; 95% CI: 0.31-0.99), zotepine (SMD: 0.71; 95% CI: 0.47-0.96) and olanzapine (SMD: 0.74; 95% CI: 0.67-0.81) and approximately (that is, no statistically significant difference at the p=0.05 level) as much as weight gain as aripiprazole (SMD: 0.17; 95% CI: 0.05-0.28), lurasidone (SMD: 0.10; 95% CI: –0.02-0.21), amisulpride (SMD: 0.20; 95% CI: 0.05-0.35), haloperidol (SMD: 0.09; 95% CI: 0.00-0.17) and ziprasidone (SMD: 0.10; 95% CI: –0.02-0.22). The same meta-analysis suggested that asenapine had a relatively high risk of extrapyramidal symptoms compared to other atypical antipsychotics but a lower risk than first-generation or typical antipsychotics.

Discontinuation

For all antipsychotics, the British National Formulary recommends a gradual dose reduction when discontinuing to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time.

There is tentative evidence that discontinuation of antipsychotics can result in psychosis as a transient withdrawal symptom. It may also result in recurrence of the condition that is being treated. Rarely tardive dyskinesia can occur when the medication is stopped.

Pharmacology

Pharmacodynamics

Asenapine shows high affinity (pKi) for numerous receptors, including the serotonin 5-HT1A (8.6), 5-HT1B (8.4), 5-HT2A (10.2), 5-HT2B (9.8), 5-HT2C (10.5), 5-HT5A (8.8), 5-HT6 (9.5), and 5-HT7 (9.9) receptors, the adrenergic α1 (8.9), α2A (8.9), α2B (9.5), and α2C (8.9) receptors, the dopamine D1 (8.9), D2 (8.9), D3 (9.4), and D4 (9.0) receptors, and the histamine H1 (9.0) and H2 (8.2) receptors. It has much lower affinity (pKi 1A receptors. At all other targets asenapine is an antagonist.

Even relative to other atypical antipsychotics, asenapine has unusually high affinity for the 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors, and very high affinity for the α2 and H1 receptors.

Notes

References

References

1. Anvisa. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. (17 September 2018). "Sycrest EPAR".
3. (14 January 2013). "Product Information Saphris (asenapine maleate)". Merck Sharp & Dohme (Australia) Pty Limited.
4. (March 2013). "Saphris (asenapine maleate) tablet". Organon Pharmaceuticals.
5. "Sycrest 5mg sublingual tablets - Summary of Product Characteristics (SmPC)".
6. (21 February 2013). "Product information Sycrest – EMEA/H/C/001177 –II/0012". N.V. Organon.
7. (2021-03-16). "Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070)". Journal of Clinical Psychopharmacology.
8. (August 2010). "Evaluation of the clinical efficacy of asenapine in schizophrenia". Expert Opinion on Pharmacotherapy.
9. (2009-08-01). "Saphris (asenapine) prescribing information". Schering Corporation.
10. "First Generic Drug Approvals".
11. (2013). "Australian Medicines Handbook". The Australian Medicines Handbook Unit Trust.
12. (May 2012). "Asenapine: a clinical review of a second-generation antipsychotic". Clinical Therapeutics.
13. (18 March 2020). "Transdermal Asenapine in Schizophrenia: A Systematic Review". Patient Preference and Adherence.
14. (November 2015). "Asenapine versus placebo for schizophrenia". The Cochrane Database of Systematic Reviews.
15. (September 2013). "Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials". International Clinical Psychopharmacology.
16. (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet.
17. (June 2011). "Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials". BMC Psychiatry.
18. (October 2012). "Which psychotropics carry the greatest risk of QTc prolongation?". Current Psychiatry.
19. (2012). "The Maudsley prescribing guidelines in psychiatry". Wiley-Blackwell.
20. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet.
21. (March 2009). "British National Formulary". Royal Pharmaceutical Society of Great Britain.
22. (2004). "Adverse Syndromes and Psychiatric Drugs: A Clinical Guide". OUP Oxford.
23. (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica.
24. (2013). "Adherence to Antipsychotics in Schizophrenia". Springer Science & Business Media.
25. (March 2009). "Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain". European Neuropsychopharmacology.
26. (January 2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature". Journal of Psychopharmacology.